Oops, you're using an old version of your browser so some of the features on this page may not be displaying properly.

MINIMAL Requirements: Google Chrome 24+Mozilla Firefox 20+Internet Explorer 11Opera 15–18Apple Safari 7SeaMonkey 2.15-2.23

Poster session 04

1232P - Assessing uncertainty and vulnerability of clinical trials with immune-checkpoint inhibitors and chemotherapy (ICI+CT) in early stage non-small cell lung cancer (NSCLC) by informative censoring and survival inferred fragility index (SIFI)

Date

14 Sep 2024

Session

Poster session 04

Topics

Pathology/Molecular Biology;  Statistics;  Immunotherapy

Tumour Site

Non-Small Cell Lung Cancer

Presenters

Antonio Nuccio

Citation

Annals of Oncology (2024) 35 (suppl_2): S775-S793. 10.1016/annonc/annonc1600

Authors

A. Nuccio1, F. Salomone2, G. Viscardi3, F.M. Venanzi4, A. Bulotta1, F.R. Ogliari5, S. Oresti6, S.T. Riva1, L. Mollica7, M.G. Viganò1, F. Passaretti8, M. RAVASI9, L. Papotto8, M. ferrara9, B. Ricciuti10, G. Veronesi11, M.C. Garassino12, V. Torri13, R. Ferrara14

Author affiliations

  • 1 Medical Oncology, IRCCS Ospedale San Raffaele, 20132 - Milan/IT
  • 2 Clinical Medicine And Surgery, Università degli Studi di Napoli Federico II - Scuola di Medicina e Chirurgia, 80131 - Napoli/IT
  • 3 Medical Oncology, AORN Ospedali dei Colli, Naples/IT
  • 4 Oncologia Medica, UniSR - Università Vita e Salute San Raffaele Milano, 20132 - Milan/IT
  • 5 Dipartimento Di Oncologia, IRCCS Ospedale San Raffaele, 20132 - Milan/IT
  • 6 Oncology Department, IRCCS Ospedale San Raffaele, 20132 - Milan/IT
  • 7 Medical Oncology, IRCCS Pavia - Istituti Clinici Scientifici Maugeri, 27100 - Pavia/IT
  • 8 Medical Oncology Dept., IRCCS Ospedale San Raffaele, 20132 - Milan/IT
  • 9 Medical Oncology, UniSR - Università Vita e Salute San Raffaele Milano, 20132 - Milan/IT
  • 10 Lowe Center For Thoracic Oncology, Dana Farber Cancer Institute, 02215 - Boston/US
  • 11 Thoracic Surgery, IRCCS Ospedale San Raffaele, 20132 - Milan/IT
  • 12 Department Of Medicine, University of Chicago Department of Medicine - Section of Hematology/Oncology, 60637-1470 - Chicago/US
  • 13 Laboratory Of Methodology For Biomedical Research, Istituto Di Ricerche Farmacologiche Mario Negri - IRCCS, 20156 - Milan/IT
  • 14 Thoracic Oncology Unit, UniSR - Università Vita e Salute San Raffaele Milano, 20132 - Milan/IT

Resources

Login to get immediate access to this content.

If you do not have an ESMO account, please create one for free.

Abstract 1232P

Background

Randomized controlled trials (RCTs) showed survival improvement with neoadjuvant/perioperative ICI + CT in early NSCLC. However, interpretation of the results can be affected by a variable level of uncertainty due to censoring imbalance and vulnerability of statistical conclusions.

Methods

PubMed, Embase and Cochrane were searched until April 2024 for RCTs comparing neoadjuvant/perioperative ICI + CT with neoadjuvant CT in patients with early-stage NSCLC. Individual Patient Data (IPD) curves and the corresponding hazard ratios (HR) were reconstructed from published EFS Kaplan-Meier data from each trial and treatment arm by using an IPD software. Reverse HR (R-HR) was obtained by flipping the status of time-dependent outcome for individual patients (reverse Kaplan Meier method) and were used to estimate censoring imbalance. SIFI was determined by iteratively transferring the best survivors from the experimental arm to the control arm until p≥0.05; conversely, negative SIFI was calculated until p<0.05.

Results

Eight RCTs (n=3387) were included. R-HR analysis showed a trend in increased censoring imbalance in the experimental arm in 1 RCT (NADIM II) and in the control arm in 2 RCTs (NeoTORCH, TD-FOREKNOW), in 1 RCT (RATIONALE-315) censoring imbalance was significantly higher in the control arm (R-HR 1.30; 95% CI 1.02-1.65). Median SIFI was 12 (IQR, 4.25 - 20.25), with absolute weighted SIFI ≤ 2% in 3 RCTs (NADIM II, AEGEAN, Checkmate 816), suggesting a potential vulnerability affecting the significance of results. Table: 1232P

Study name N IPD-HR R-HR (control vs experimental) SIFI (%) Median FUP months (range, if specified)
AEGEAN 740 0.70 (0.54 - 0.91) 0.96 (0.80 - 1.15) 9 (1) 11.7
NADIM II 86 0.43 (0.21 - 0.86) 0.51 (0.23 - 1.13) 2 (2) 26.1 (17.4 - 30.9)
CheckMate 816 358 0.66 (0.48-0.91) 1.06 (0.80 - 1.41) 5 (1) 41.4
NeoTORCH 404 0.39 (0.28 - 0.54) 1.12 (0.86 - 1.47) 33 (8) 18.3
KEYNOTE 671 797 0.57 (0.46 - 0.70) 0.99 (0.81 - 1.19) 37 (5) 25.2 (7.5 - 50.6)
CheckMate 77T 461 0.58 (0.44 - 0.78) 1 (0.78 - 1.28) 15 (3) 25.4 (15.7 - 44.2)
TD-FOREKNOW 88 0.53 (0.21 - 1.30) 1.33 (0.81 - 2.19) -4 (5) 14.1 (9.2 - 20.9)
RATIONALE-315 453 0.56 (0.40 - 0.79) 1.30 (1.02 - 1.65) 16 (4) 22.0

Conclusions

Significant censoring imbalance in the control arm and high survival fragility were reported in 1 and 3 RCTs, respectively, suggesting that informative censoring and survival vulnerability are useful tools to ensure a reliable interpretation of data.

Clinical trial identification

Legal entity responsible for the study

The authors.

Funding

Has not received any funding.

Disclosure

All authors have declared no conflicts of interest.

This site uses cookies. Some of these cookies are essential, while others help us improve your experience by providing insights into how the site is being used.

For more detailed information on the cookies we use, please check our Privacy Policy.

Customise settings
  • Necessary cookies enable core functionality. The website cannot function properly without these cookies, and you can only disable them by changing your browser preferences.